Pharmafile Logo
Pharmafocus logo
Advanced Search
carlos-muza-hpjsku2uysu-unsplash_1

AstraZeneca launches health-tech business, Evinova

November 21, 2023
Business Services AstraZeneca, Pharmacy, health-tech

AstraZeneca has announced that it has launched Evinova, its new health-tech business, which it is hoped will become a leading …

News

Almirall gains EC approval of Ebglyss for moderate-to-severe atopic dermatitis

November 20, 2023
Medical Communications Almirall, Dermatology, Ebglyss, European Commission, atopic dermatitis

Almirall has announced that the European Commission (EC) has approved Ebglyss (lebrikizumab) for the treatment of adult and adolescent patients …

News

Astellas Pharma to acquire Propella Therapeutics for $175m

November 20, 2023
Business Services Astellas Pharma, Oncology, Properlla Therapeutics, acquisition

Astellas Pharma and Propella Therapeutics have announced that Astellas and Propella have entered a merger agreement in which Astellas will …

News

FDA approves AstraZeneca’s Truqap plus Faslodex for breast cancer treatment

November 17, 2023
Medical Communications AstraZeneca, FDA, Faslodex, Oncology, breast cancer

AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Truqap (capivasertib) in combination with Faslodex (fullvestrant) …

News

FDA approves Merck’s Keytruda for gastric cancer treatment

November 17, 2023
Medical Communications FDA, MSD, Merck, Oncology, gastric cancer, keytruda

Merck, known as MSD outside of the US, has announced that the US Food and Drug Administration (FDA) has approved …

News

FDA approves BMS’s Augtyro for lung cancer treatment

November 16, 2023
Medical Communications FDA, Oncology, bristol myers squibb, lung cancer

Bristol Myers Squibb has announced that the US Food and Drug Administration (FDA) has approved Augtyro (repotrectinib) for the treatment …

News

Prange Group and Adragos Pharma to acquire Fresenius Kabi’s manufacturing site

November 16, 2023
Business Services Fresenius Kabi, Pharmacy, Prange Group, acquisition

Prange Group and Adragos Pharma have announced the signing of definitive agreements with Fresenius Kabi for their acquisition of its …

News

Kesin Pharma’s Likmez approved by FDA

November 15, 2023
Medical Communications Kesin Pharma, Likmez, Pharmacy, Saptalis Pharmaceuticals, antibiotic

Kesin Pharma has announced that the US Food and Drug Administration (FDA) has approved Likmez (metronidazole) oral suspension, 500mg/5mL, for …

News

Alvotech and JAMP Pharma’s Jamteki gains marketing authorisation from Health Canada

November 15, 2023
Medical Communications Alvotech, Health Canada, JAMP Pharma, Pharmacy, biosimilar

Alvotech and JAMP Pharma have announced that Health Canada has granted JAMP Pharma marketing authorisation for AVT04, a biosimilar to …

News
milad-fakurian-58z17lnvs4u-unsplash_2

Autifony announces global license and collaboration agreement with Jazz Pharmaceuticals

November 14, 2023
Business Services Autifony, Neurology, collaboration, jazz pharmaceuticals, neurological disorders

Autifony Therapeutics has announced that it has entered an exclusive global licensing agreement with Jazz Pharmaceuticals for up to $770.5m, …

News

Health Canada approves Ipsen and Medision Pharma’s Bylvay for pruritus treatment

November 14, 2023
Medical Communications Health Canada, Medision Pharma, Rare Diseases, ipsen, pruritis

Ipsen and Medision Pharma have announced that Health Canada has approved Bylvay (odevixibat) for the treatment of pruritis in patients …

News

Enhanc3D Genomics appoints Hazel Jones as chief operating officer

November 14, 2023
Business Services Enhanc3D Genomics, Hazel Jones, chief operating officer

Enhanc3D Genomics has announced the appointment of Hazel Jones as chief operating officer. This appointment marks part of the company’s …

Appointment

Anthony Johnson appointed NanoSyrinx’s non-executive director

November 14, 2023
Business Services Anthony Johnson, NanoSyrinx, non-executive director

NanoSyrinx has announced the appointment of Anthony Johnson MD to its board as non-executive director. This appointment marks part of …

Appointment
testalize-me-0je8ynv4mis-unsplash

GSK gains positive CHMP opinion for momelotinib for myelofibrosis treatment

November 13, 2023
Medical Communications CHMP, GSK, Haematology, anaemia, momelotinib, myelofibrosis

GSK has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has …

News

AstraZeneca’s Imfinzi meets primary endpoint for liver cancer treatment

November 13, 2023
Research and Development AstraZeneca, Imfinzi, Oncology, clinical trial, liver cancer

AstraZeneca has announced positive results from the EMERALD-1 phase 3 trial for Imfinzi (durvalumab) in combination with transarterial chemoembolisation (TACE) …

News

Daiichi Sankyo’s Vanflyta approved by EC for acute myeloid leukaemia treatment

November 10, 2023
Medical Communications Daiichi Sankyo, EC, EU, Oncology, Vanflyta, acute myeloid leukaemia

Daiichi Sankyo has announced that Vanflyta (quizartinib) has been approved in the EU for combination use with standard cytarabine and …

News
glsun-mall-9xmv81sz5fw-unsplash

Novo Nordisk invests 42bn Danish kroner to expand facilities in Kalundborg, Denmark

November 10, 2023
Manufacturing and Production Chronic Diseases, Denmark, Novo Nordisk, investment, manufacturing

Novo Nordisk have announced plans to invest over 42bn Danish kroner to expand its existing manufacturing facilities in Kalundbord, Denmark, …

News

Eli Lilly’s Zepbound approved by FDA for chronic weight management

November 9, 2023
Medical Communications Eli Lilly, FDA, Obesity, Zepbound, weight loss, weight management

Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Zepbound (tirzepatide) injection for chronic weight …

News
national-cancer-institute-kmvohcb-w5g-unsplash_1

First patient dosed in AdvanCell’s phase 1/2 trial for prostate cancer treatment

November 9, 2023
Research and Development AdvanCell, Cancer, Oncology, clinical trial, prostate cancer

AdvanCell has announced that the first patient has been dosed with 212Pb-ADVC001 in its phase 1/2 trial for the PSMA-positive …

News

J&J’s to submit surgical robot to FDA in 2024

November 8, 2023
Research and Development FDA, J&J, Johnson & Johnson MedTech, Pharmacy, surgical robot

Johnson & Johnson MedTech have announced plans to submit the Ottava robotic surgical system to the US Food and Drug …

News

Latest content

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024

AskBio initiates phase 2 Parkinson’s trial recruitment

June 26, 2024

AstraZeneca’s Tagrisso approved in Japan for lung cancer treatment

June 25, 2024

ILiAD Biotechnologies announces collaboration with Emmes Group on phase 3 pertussis vaccine trial

June 25, 2024

GSK’s Jemperli accepted for review by EMA for endometrial cancer treatment

June 24, 2024